Project Grant R44GM165165
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Waltham, MA 02451, USA
Similar Awards
- The National Science Foundation awarded Beken Bio, Inc. a $1,249,464 cooperative agreement on August 1, 2026, under the SBIR Phase II program to develop a liquid biopsy diagnostic tool that detects cancer through extracellular vesicle biomarkers in blood samples. The recipient will conduct a prospective, blinded clinical study of approximately 300 patients undergoing surgery to validate a diagnostic test that measures cancer signals carried by extracellular vesicles (EVs)—tiny particles released...
- This $500,000 National Science Foundation project grant supports research to advance the biom anufacturing of extracellular vesicles through the integration of human induced pluripotent stem cell technology, genome engineering, and membrane nanofabrication. The primary recipient is Syracuse University, with Rochester Institute of Technology serving as a sub-awardee. Under the Biological Sciences program (CFDA 47.074), the grantees will work to generate a stable human iPSC line with enhanced EV...
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of extracellular vesicles (EVs) as therapeutic carriers. The $622,000 award, effective August 1, 2024 through July 31, 2027, will enable researchers at The Washington University in St. Louis to engineer endothelial cell-derived EVs to efficiently...
- The National Institute of Biomedical Imaging and Bioengineering awarded $318,676 to Massachusetts General Hospital on February 13, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and validate a microfluidic chip technology for high-throughput loading of cryoprotective agents into therapeutic allogeneic immune cells. The project, titled VELCPA (Veloporation for CPA Loading), addresses cell cryopreservation...
- The National Institute of General Medical Sciences awarded Sansimeon Inc. $382,798 under the Biomedical Research and Research Training program (CFDA 93.859) on June 15, 2026, to develop a fully integrated platform for reproducible and scalable single-cell sequencing in clinical research. Sansimeon is developing a turnkey platform that unifies red blood cell and platelet removal, cell enrichment, multiplexed tagging, and CITE-SEQ labeling into a streamlined one-step workflow, eliminating...
- Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...
- The National Science Foundation awarded Cytorecovery Inc. a $255,986 Small Business Technology Transfer Phase I Project Grant under the Engineering program (CFDA 47.041) on March 15, 2021. The grant funded the development of on-chip integration of sample preparation and monitoring capabilities with dielectrophoretic cell isolation techniques. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award...
- The National Institute of General Medical Sciences awarded Physical Sciences Inc. $311,847 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a fluorescence-based rapid phage detection system for industrial bioreactors. Physical Sciences Inc. and the University of Connecticut are developing a lyobead assay platform that detects bacteriophage contamination in bioreactor systems within hours. The system uses a sampling chamber loaded with...
- The National Cancer Institute awarded Electronic Biosciences, Inc. $418,854 on June 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a next-generation single-molecule protein sequencing platform for oncoproteomic analysis. The project delivers a nanopore-based sequencing system capable of directly sequencing individual proteins, identifying variants, and profiling post-translational modifications such as phosphorylation and glycosylation. The platform addresses...
- The National Institute of General Medical Sciences awarded Partillion Bioscience Corp $979,071 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop nanovial kits for large-scale cell-cell interaction sequencing. Partillion will expand compatibility of nanovials—engineered hydrogel microcontainers that compartmentalize single-cell and cell-pair interactions—across widely used off-the-shelf single-cell sequencing chemistries to broaden user...